Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer
NL-OMON60509Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of volrustomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival (PFS) in PD-L1 <1% and Overall Survival (OS) in PD-L1 <1%. Started Jul 2024; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60509.